Real-world daptomycin use across wide geographical regions

Results from a pooled analysis of CORE and EU-CORE

R. Andrew Seaton, Armando Gonzalez-Ruiz, Kerry Cleveland, Kimberly A. Couch, Rashidkhan Pathan, Kamal Hamed

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Pooled data from two large registries, Cubicin� Outcomes Registry and Experience (CORE; USA) and European Cubicin� Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions. Methods: Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Grampositive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment. Results: In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of highdose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively. Conclusions: The real-world data showed that daptomycin was effective and safe in the treatment of various Grampositive infections, including those caused by resistant pathogens, across wide geographical regions.

Original languageEnglish (US)
Article number18
JournalAnnals of Clinical Microbiology and Antimicrobials
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Daptomycin
Infection
Osteomyelitis
Foreign Bodies
Endocarditis
Registries
Bacteremia
Equipment and Supplies
Therapeutics
Orthopedics
Soft Tissue Infections
Latin America
Methicillin-Resistant Staphylococcus aureus
Staphylococcus aureus
Diabetes Mellitus
Cardiovascular Diseases

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Real-world daptomycin use across wide geographical regions : Results from a pooled analysis of CORE and EU-CORE. / Andrew Seaton, R.; Gonzalez-Ruiz, Armando; Cleveland, Kerry; Couch, Kimberly A.; Pathan, Rashidkhan; Hamed, Kamal.

In: Annals of Clinical Microbiology and Antimicrobials, Vol. 15, No. 1, 18, 01.01.2016.

Research output: Contribution to journalArticle

Andrew Seaton, R. ; Gonzalez-Ruiz, Armando ; Cleveland, Kerry ; Couch, Kimberly A. ; Pathan, Rashidkhan ; Hamed, Kamal. / Real-world daptomycin use across wide geographical regions : Results from a pooled analysis of CORE and EU-CORE. In: Annals of Clinical Microbiology and Antimicrobials. 2016 ; Vol. 15, No. 1.
@article{16666a1f4eed4ae0919a185766c9e9b5,
title = "Real-world daptomycin use across wide geographical regions: Results from a pooled analysis of CORE and EU-CORE",
abstract = "Background: Pooled data from two large registries, Cubicin� Outcomes Registry and Experience (CORE; USA) and European Cubicin� Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions. Methods: Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Grampositive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment. Results: In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 {\%}) and diabetes mellitus (28.0 {\%}). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 {\%}) and bacteremia (21.8 {\%}). The overall clinical success rate was 77.2 {\%} (uncomplicated SSTI, 88.3 {\%}; cSSTI, 81.0 {\%}; osteomyelitis, 77.7 {\%}; foreign body/prosthetic infection (FBPI), 75.9 {\%}; endocarditis, 75.4 {\%}; and bacteremia, 69.5 {\%}). The clinical success rate was 79.1 {\%} in patients with Staphylococcus aureus infections (MRSA, 78.1 {\%}). An increasing trend of highdose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 {\%}) and 133 (1.2 {\%}) patients, respectively. Conclusions: The real-world data showed that daptomycin was effective and safe in the treatment of various Grampositive infections, including those caused by resistant pathogens, across wide geographical regions.",
author = "{Andrew Seaton}, R. and Armando Gonzalez-Ruiz and Kerry Cleveland and Couch, {Kimberly A.} and Rashidkhan Pathan and Kamal Hamed",
year = "2016",
month = "1",
day = "1",
doi = "10.1186/s12941-016-0130-8",
language = "English (US)",
volume = "15",
journal = "Annals of Clinical Microbiology and Antimicrobials",
issn = "1476-0711",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Real-world daptomycin use across wide geographical regions

T2 - Results from a pooled analysis of CORE and EU-CORE

AU - Andrew Seaton, R.

AU - Gonzalez-Ruiz, Armando

AU - Cleveland, Kerry

AU - Couch, Kimberly A.

AU - Pathan, Rashidkhan

AU - Hamed, Kamal

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: Pooled data from two large registries, Cubicin� Outcomes Registry and Experience (CORE; USA) and European Cubicin� Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions. Methods: Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Grampositive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment. Results: In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of highdose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively. Conclusions: The real-world data showed that daptomycin was effective and safe in the treatment of various Grampositive infections, including those caused by resistant pathogens, across wide geographical regions.

AB - Background: Pooled data from two large registries, Cubicin� Outcomes Registry and Experience (CORE; USA) and European Cubicin� Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions. Methods: Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Grampositive infections were included. Clinical success was defined as an outcome of 'cured' or 'improved'. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment. Results: In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1-103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of highdose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively. Conclusions: The real-world data showed that daptomycin was effective and safe in the treatment of various Grampositive infections, including those caused by resistant pathogens, across wide geographical regions.

UR - http://www.scopus.com/inward/record.url?scp=85007473638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007473638&partnerID=8YFLogxK

U2 - 10.1186/s12941-016-0130-8

DO - 10.1186/s12941-016-0130-8

M3 - Article

VL - 15

JO - Annals of Clinical Microbiology and Antimicrobials

JF - Annals of Clinical Microbiology and Antimicrobials

SN - 1476-0711

IS - 1

M1 - 18

ER -